Podcasts

Episode 54 | The Emerging Role of the Microbiome in Lung Cancer and Immunotherapy Response

In this episode features Dr. Anna McLean, Dr Mark Adams, and Dr Sagun Parakh, discussing research on the microbiome and its influence on lung cancer treatment outcomes.

Episode Summary

This episode of ‘Conversations in Lung Cancer Research’ features Dr. Anna McLean, Dr Mark Adams, and Dr Sagun Parakh, discussing research on the microbiome and its influence on lung cancer treatment outcomes. They delve into the differences between the gut and lung microbiomes, methods for studying these microorganisms, and the potential for the microbiome to serve as biomarkers for treatment response and immune-related adverse events. They also cover the importance of collaboration and larger data sets in advancing this promising area of research

 Show Guest

  • Dr Anna Mclean is a Respiratory Physician. They are an active member of a multidisciplinary cancer care team that coordinates care for people with cancer.
  •  Dr Mark Adams is currently a Strategic Research Fellow at Queensland University of Technology (QUT).

  • Dr Sagun Parakh is a Consultant Medical Oncologist, specialising in lung cancer and primary brain tumours.

Links 

Images of Dr Anna McLean, Dr Mark Adams, and Dr Sagun Parak Text: The Emerging Role of the Microbiome in Lung Cancer and Immunotherapy Response

Play Episode 54 | The Emerging Role of the Microbiome in Lung Cancer and Immunotherapy Response

More Podcasts

Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,
Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.
A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.
Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.
Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.
Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.